General Information of Drug (ID: DMSDBPG)

Drug Name
KN046 Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMSDBPG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ipilimumab DMJTIYK Melanoma 2C30 Approved [3]
Tremelimumab DMOQ9H1 Hepatocellular carcinoma 2C12.02 Approved [4]
AK04 DMU7K86 Actinic keratosis EK90.0 Phase 3 [5]
AK104 DMXJ8Z4 Cervical cancer 2C77.0 Phase 2 [6]
Lorigerlimab DM2E8Z5 Prostate cancer 2C82.0 Phase 2 [7]
Vudalimab DMSEEI0 Prostate cancer 2C82.0 Phase 2 [8]
AGEN1884 DMAP5B4 Cervical cancer 2C77.0 Phase 1/2 [9]
BMS-986288 DMM10J4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
MK-1308 DM25QKC Solid tumour/cancer 2A00-2F9Z Phase 1/2 [11]
Zalifrelimab DMNNYAE Cervical cancer 2C77.0 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Avelumab DMSZLJR Merkel cell carcinoma 2C34 Approved [13]
Durvalumab DM4PVDY Urothelial carcinoma 2C92.0 Approved [14]
RG-7446 DM69XMQ Urothelial carcinoma 2C92.0 Approved [15]
Bavencio DMU9C8F Merkel cell carcinoma 2C34 Approved [16]
Atezolizumab DMMF8U0 Non-small-cell lung cancer 2C25 Approved [17]
Sugemalimab DMH5YQ3 Non-small-cell lung cancer 2C25 Approved in China [18]
MEDI4736 DM5X849 Solid tumour/cancer 2A00-2F9Z Phase 3 [19]
MPDL-3280A DM9K3LM Melanoma 2C30 Phase 3 [20]
CS1001 DMSY0NE Non-small-cell lung cancer 2C25 Phase 3 [21]
A167 DME00MM Nasopharyngeal carcinoma 2B6B Phase 3 [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Inhibitor [2]
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04474119) KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Alphamab Oncology.
3 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
5 A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
6 Clinical pipeline report, company report or official report of Akeso Biopharma.
7 Clinical pipeline report, company report or official report of MacroGenics
8 Clinical pipeline report, company report or official report of Xencor
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Clinical pipeline report, company report or official report of CytomX Therapeutics.
11 Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
12 Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771.
13 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
15 PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
16 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
18 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
19 National Cancer Institute Drug Dictionary (drug id 740856).
20 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
21 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
22 Clinical pipeline report, company report or official report of Klus Pharma